New Low-cost Device Rapidly, Accurately Detects Hepatitis C Infection

The entire virus detection process is executed inside a uniquely designed, portable, inexpensive, disposable, and self-driven microfluidic chip. The fully automated sample-in–answer-out molecular diagnostic set-up rapidly detects Hepatitis C virus in about 45 minutes and uses relatively inexpensive and reusable equipment costing about $50 for sample processing and disease detection. The disposable microfluidic chip also offers shorter times for a reliable diagnosis and costs about $2.

COVID-19 research campaign moves from basic science to antiviral drug design

ORNL researchers have developed and tested novel small-molecule antivirals in an effort to design new drugs to treat COVID-19. The so called hybrid inhibitor molecules are made from repurposed drugs used to treat hepatitis C and the original coronavirus outbreak in the early 2000s. The experimental research results show the molecules are similarly as effective as some of the leading drugs on the market today.

Hepatitis C Infections Among Pregnant People Increased Substantially Between 2009 and 2019

The leading cause of HCV in the U.S. is injection drug use as a result of opioid use disorder (OUD), which has seen a rise in most populations, including pregnant people, in recent years. HCV rates have also risen. Between 2009 and 2019, the overall rate per 1,000 live births of HCV in pregnant people increased from 1.8 to 5.1.

August Issue of Issue of The American Journal of Gastroenterology Includes Diet-Associated NAFLD Risk and Increased Risk of Mortality from COVID-19 Among PPI Users

The August issue of The American Journal of Gastroenterology includes clinical discussions of diet-associated NAFLD risk and increased risk of mortality from COVID-19 among PPI users. In addition, this issue features clinical research and reviews on IBS, gender barriers for CRC screening, hepatitis C, eosinophilic esophagitis, and more.

More Women Diagnosed with HCV During Pregnancy, but Many Infants Still Not Tested Despite Recommendations from Leading Health Organizations

Data from a new study presented this week at The Liver Meeting Digital Experience® – held by the American Association for the Study of Liver Diseases (AASLD)– found that among pregnant women with hepatitis C virus (HCV), more than 25 percent were initially diagnosed during pregnancy screenings, which supports prenatal care as an important opportunity to screen for HCV in women. However, the study also found that less than one third of infants receive appropriate HCV testing, a significant care gap.

Racial Inequalities in Liver Cancer Deaths Soared After Launch of Hepatitis C Drugs

A study explored racial inequalities in death from liver cancer before and after the introduction of lifesaving drugs for hepatitis C. Results showed that from 1979 to 1998, racial inequalities in mortality from liver cancer in the U.S. were declining. But, from 1998 to 2016, of the 16,770 deaths from liver cancer among blacks, the excess relative to whites increased from 27.8 percent to 45.4 percent. Concurrently, racial inequalities in death decreased for major risk factors for liver cancer, such as alcohol and diabetes.

House Drug Pricing Bill Serves Patients, Public Health

H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act passed by the House of Representatives today introduces critically needed and significant steps to reduce costs and improve access to life-saving therapies for conditions including HIV and hepatitis C. Importantly, the legislation also brings essential resources to combat antibiotic resistance, find and develop new infection fighting drugs and bring them to market. The balanced approach of this legislation will serve patients and public health.

All-Oral Direct-Acting Antiviral Treatments Improve Survival in Patients with HCV-Related Hepatocellular Carcinoma

Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that hepatitis C virus-related hepatocellular carcinoma (HCC) patients who achieved sustained virologic response (SVR) – denoting an undetectable level of HCV virus – with any oral direct-acting antiviral (DAA) had over 60-70 percent improvement in five-year survival.